EMERGENT BIOSOLUTIONS INC. Share-based Payment Arrangement, Expense, Tax Benefit
EMERGENT BIOSOLUTIONS INC. (EBS) reported Share-based Payment Arrangement, Expense, Tax Benefit of $1.70 million for the 3-month period ending 2021-09-30, per its 10-Q filed 2021-11-05.
Discontinued › Expense Statement › Income Tax
us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense · last filed 2021-11-05
- EMERGENT BIOSOLUTIONS INC. share-based payment arrangement, expense, tax benefit for the quarter ending 2021-09-30 was $1.70M, a 48.48% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. share-based payment arrangement, expense, tax benefit for the quarter ending 2021-06-30 was -$1.10M, a 132.35% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. share-based payment arrangement, expense, tax benefit for the quarter ending 2021-03-31 was $6.60M, a 106.25% increase year-over-year.
- EMERGENT BIOSOLUTIONS INC. share-based payment arrangement, expense, tax benefit for the quarter ending 2020-09-30 was $3.30M.
| Period end | Share-based Payment Arrangement, Expense, Tax Benefit 3 month | Share-based Payment Arrangement, Expense, Tax Benefit 6 month | Share-based Payment Arrangement, Expense, Tax Benefit 9 month | Share-based Payment Arrangement, Expense, Tax Benefit 9 month as first filed |
|---|---|---|---|---|
| 2021-09-30 | $1.70M 10-Q · filed 2021-11-05 | $600.00K derived: sum of 2 quarters · filed 2021-11-05 | $7.20M 10-Q · filed 2021-11-05 | |
| 2021-06-30 | -$1.10M 10-Q · filed 2021-07-30 | $5.50M 10-Q · filed 2021-07-30 | ||
| 2021-03-31 | $6.60M 10-Q · filed 2021-04-30 | |||
| 2020-09-30 | $3.30M 10-Q · filed 2021-11-05 | $6.70M derived: sum of 2 quarters · filed 2021-11-05 | $9.90M 10-Q · filed 2021-11-05 | |
| 2020-06-30 | $3.40M 10-Q · filed 2021-07-30 | $6.60M 10-Q · filed 2021-07-30 | ||
| 2020-03-31 | $3.20M 10-Q · filed 2021-04-30 | |||
| 2019-09-30 | -$200.00K 10-Q · filed 2020-11-06 | $1.20M derived: sum of 2 quarters · filed 2020-11-06 | $2.90M 10-Q · filed 2020-11-06 | $3.00M 10-Q · filed 2019-11-07 |
| 2019-06-30 | $1.40M 10-Q · filed 2020-07-31 | $3.20M 10-Q · filed 2020-07-31 | ||
| 2019-03-31 | $1.80M 10-Q · filed 2020-05-01 | |||
| 2018-09-30 | $5.50M 10-Q · filed 2019-11-07 | $6.40M derived: sum of 2 quarters · filed 2019-11-07 | $8.70M 10-Q · filed 2019-11-07 | |
| 2018-06-30 | $900.00K 10-Q · filed 2019-08-02 | $3.20M 10-Q · filed 2019-08-02 | ||
| 2018-03-31 | $2.30M 10-Q · filed 2019-05-08 | |||
| 2017-09-30 | $2.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-02 | $2.20M derived: sum of 2 quarters · filed 2018-11-02 | $3.30M 10-Q · filed 2018-11-02 | |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-03 | $1.10M 10-Q · filed 2018-08-03 | ||
| 2017-03-31 | $1.10M 10-Q · filed 2018-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |